Adam H. Skolnick, MD


September 29, 2014

In the past four years, three novel oral anticoagulant (NOAC) medications have become available: apixaban (Eliquis®), dabigatran (Pradaxa®), and rivaroxaban (Xarelto®). A fourth NOAC, edoxaban (Savaysa™), has been submitted for approval by the US Food and Drug Administration (FDA).

Although it is exciting to have so many alternatives to warfarin, the appropriate use of these medications is essential. There are no direct comparison data for these drugs, but we can draw some inferences from the major NOAC trials.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: